Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain Therapeutics

What are the Strengths, Weaknesses, Opportunities and Threats of

Home Perspectives from Gain Therapeutics

Gain Therapeutics Announces Closing of Initial Public

Is Gain Therapeutics Inc (GANX) Stock About to Get Hot Thursday?

Gain Therapeutics and UMSOM Partner to Investigate Small Molecule

Gain Therapeutics: A True Revolution In Drug Development (NASDAQ

Gain Therapeutics Presents New Preclinical Data of Drug Candidate

Gain Therapeutics

Gain Therapeutics (@GainThera) / X

Gain Therapeutics' Small Molecule Approach for CNS Diseases

Is Gain Therapeutics Inc (GANX) Stock a Good Value Tuesday?

Gain Therapeutics presents hopeful data for Parkinson's, Gaucher

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

Gain's clinical Parkinson's drug restores motor function in mice